Cite
MA08.03 Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis
MLA
Sabina Patel, et al. “MA08.03 Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma CtDNA Analysis.” Journal of Thoracic Oncology, vol. 12, Jan. 2017, p. S386. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........5d4211e898e3a83244702f66cf9190d9&authtype=sso&custid=ns315887.
APA
Sabina Patel, Te Chun Hsia, Suzanne Jenkins, Sang-We Kim, Janessa Laskin, Vassiliki A. Papadimitrakopoulou, Yong He, Tony Mok, Marcelo Marotti, Rachel Hodge, Angelo Delmonte, Yi-Long Wu, Ji-Youn Han, & Suresh S. Ramalingam. (2017). MA08.03 Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis. Journal of Thoracic Oncology, 12, S386.
Chicago
Sabina Patel, Te Chun Hsia, Suzanne Jenkins, Sang-We Kim, Janessa Laskin, Vassiliki A. Papadimitrakopoulou, Yong He, et al. 2017. “MA08.03 Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma CtDNA Analysis.” Journal of Thoracic Oncology 12 (January): S386. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........5d4211e898e3a83244702f66cf9190d9&authtype=sso&custid=ns315887.